Role of the nitric oxide/cyclic GMP pathway and extracellular environment in the nitric oxide donor-induced increase in dopamine secretion from PC12 cells: a microdialysis in vitro study

J Neurochem. 2003 Sep;86(6):1403-13. doi: 10.1046/j.1471-4159.2003.01947.x.

Abstract

In vitro microdialysis was used to investigate the mechanism of nitric oxide (NO) donor-induced changes in dopamine (DA) secretion from PC12 cells. Infusion of the NO-donor S-nitroso-N-acetylpenicillamine (SNAP, 1.0 mm) induced a long-lasting increase in DA and 3-methoxytyramine (3-MT) dialysate concentrations. SNAP-induced increases were inhibited either by pre-infusion of the soluble guanylate cyclase (sGC) inhibitor 1H-[1,2,4] oxadiazolo[4,3]quinoxalin-1-one (ODQ, 0.1 mm) or by Ca2+ omission. Ca2+ re-introduction restored SNAP effects. SNAP-induced increases in DA + 3-MT were unaffected by co-infusion of the l-type Ca2+ channel inhibitor nifedipine. The NO-donor (+/-)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide (NOR-3, 1.0 mm) induced a short-lasting decrease in dialysate DA + 3-MT. Ascorbic acid (0.2 mm) co-infusion allowed NOR-3 to increase dialysate DA + 3-MT. ODQ pre-infusion inhibited NOR-3 + ascorbic acid-induced DA + 3-MT increases. Infusion of high K+ (75 mm) induced a 2.5-fold increase in dialysate DA + 3-MT. The increase was abolished by NOR-3 co-infusion. Conversely, co-infusion of ascorbic acid (0.2 mm) with NOR-3 + high K+ restored high K+ effects. Co-infusion of nifedipine inhibited high K+-induced DA + 3-MT increases. These results suggest that activation of the NO/sGC/cyclic GMP pathway may be the underlying mechanism of extracellular Ca2+-dependent effects of exogenous NO on DA secretion from PC12 cells. Extracellular Ca2+ entry may occur through nifedipine-insensitive channels. NO effects and DA concentrations in dialysates largely depend on both the timing of NO generation and the extracellular environment in which NO is generated.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3,4-Dihydroxyphenylacetic Acid / analysis
  • 3,4-Dihydroxyphenylacetic Acid / metabolism
  • Animals
  • Ascorbic Acid / pharmacology
  • Calcium / metabolism
  • Calcium Channel Blockers / pharmacology
  • Cell Survival
  • Cyclic GMP / metabolism*
  • Dopamine / analogs & derivatives*
  • Dopamine / analysis
  • Dopamine / metabolism*
  • Enzyme Inhibitors / pharmacology
  • Extracellular Space / chemistry
  • Extracellular Space / metabolism*
  • Homovanillic Acid / analysis
  • Homovanillic Acid / metabolism
  • Microdialysis
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / pharmacology*
  • Nitro Compounds / pharmacology
  • PC12 Cells
  • Pheochromocytoma / drug therapy
  • Pheochromocytoma / metabolism*
  • Potassium / metabolism
  • Rats
  • S-Nitroso-N-Acetylpenicillamine / pharmacology

Substances

  • Calcium Channel Blockers
  • Enzyme Inhibitors
  • Nitric Oxide Donors
  • Nitro Compounds
  • 3,4-Dihydroxyphenylacetic Acid
  • Nitric Oxide
  • S-Nitroso-N-Acetylpenicillamine
  • FK 409
  • Cyclic GMP
  • 3-methoxytyramine
  • Ascorbic Acid
  • Potassium
  • Calcium
  • Dopamine
  • Homovanillic Acid